ArticleThe Lancet. Haematology2019
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
Ghadeer K Dawwas et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
36 papers cite it
this paperpooled itcites it